Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics from In Vitro Data.

Jones HM, Zhang Z, Jasper P, Luo H, Avery LB, King LE, Neubert H, Barton HA, Betts AM, Webster R.

CPT Pharmacometrics Syst Pharmacol. 2019 Aug 29. doi: 10.1002/psp4.12461. [Epub ahead of print]

2.

Structure-Activity Study of Antibacterial Poly(ester urethane)s with Uniform Distribution of Hydrophobic and Cationic Groups.

Peng C, Vishwakarma A, Mankoci S, Barton HA, Joy A.

Biomacromolecules. 2019 Apr 8;20(4):1675-1682. doi: 10.1021/acs.biomac.9b00029. Epub 2019 Mar 21.

PMID:
30844254
3.

High Microbial Diversity Despite Extremely Low Biomass in a Deep Karst Aquifer.

Hershey OS, Kallmeyer J, Wallace A, Barton MD, Barton HA.

Front Microbiol. 2018 Nov 26;9:2823. doi: 10.3389/fmicb.2018.02823. eCollection 2018.

4.

Post-fabrication QAC-functionalized thermoplastic polyurethane for contact-killing catheter applications.

Zander ZK, Chen P, Hsu YH, Dreger NZ, Savariau L, McRoy WC, Cerchiari AE, Chambers SD, Barton HA, Becker ML.

Biomaterials. 2018 Sep;178:339-350. doi: 10.1016/j.biomaterials.2018.05.010. Epub 2018 May 11.

PMID:
29784475
5.

High-Throughput Sequencing Analysis of the Actinobacterial Spatial Diversity in Moonmilk Deposits.

Maciejewska M, Całusińska M, Cornet L, Adam D, Pessi IS, Malchair S, Delfosse P, Baurain D, Barton HA, Carnol M, Rigali S.

Antibiotics (Basel). 2018 Mar 21;7(2). pii: E27. doi: 10.3390/antibiotics7020027.

6.

The U.S. Culture Collection Network Responding to the Requirements of the Nagoya Protocol on Access and Benefit Sharing.

McCluskey K, Barker KB, Barton HA, Boundy-Mills K, Brown DR, Coddington JA, Cook K, Desmeth P, Geiser D, Glaeser JA, Greene S, Kang S, Lomas MW, Melcher U, Miller SE, Nobles DR Jr, Owens KJ, Reichman JH, da Silva M, Wertz J, Whitworth C, Smith D.

MBio. 2017 Aug 15;8(4). pii: e00982-17. doi: 10.1128/mBio.00982-17. Review.

7.

Assessment of the Potential Role of Streptomyces in Cave Moonmilk Formation.

Maciejewska M, Adam D, Naômé A, Martinet L, Tenconi E, Całusińska M, Delfosse P, Hanikenne M, Baurain D, Compère P, Carnol M, Barton HA, Rigali S.

Front Microbiol. 2017 Jun 29;8:1181. doi: 10.3389/fmicb.2017.01181. eCollection 2017.

9.

A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human.

Karelina T, Demin O, Nicholas T, Lu Y, Duvvuri S, Barton HA.

CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):666-675. doi: 10.1002/psp4.12211. Epub 2017 Aug 10.

10.

Nontoxic Cationic Coumarin Polyester Coatings Prevent Pseudomonas aeruginosa Biofilm Formation.

Chamsaz EA, Mankoci S, Barton HA, Joy A.

ACS Appl Mater Interfaces. 2017 Mar 1;9(8):6704-6711. doi: 10.1021/acsami.6b12610. Epub 2017 Feb 17.

PMID:
28150937
11.

Genomic characterization of eight Ensifer strains isolated from pristine caves and a whole genome phylogeny of Ensifer (Sinorhizobium).

Kumar HK, Gan HM, Tan MH, Eng WW, Barton HA, Hudson AO, Savka MA.

J Genomics. 2017 Jan 18;5:12-15. doi: 10.7150/jgen.17863. eCollection 2017.

12.

A diverse intrinsic antibiotic resistome from a cave bacterium.

Pawlowski AC, Wang W, Koteva K, Barton HA, McArthur AG, Wright GD.

Nat Commun. 2016 Dec 8;7:13803. doi: 10.1038/ncomms13803.

13.

A Phenotypic and Genotypic Analysis of the Antimicrobial Potential of Cultivable Streptomyces Isolated from Cave Moonmilk Deposits.

Maciejewska M, Adam D, Martinet L, Naômé A, Całusińska M, Delfosse P, Carnol M, Barton HA, Hayette MP, Smargiasso N, De Pauw E, Hanikenne M, Baurain D, Rigali S.

Front Microbiol. 2016 Sep 21;7:1455. eCollection 2016.

14.

Limnodrilus sulphurensis n. sp., from a sulfur cave in Colorado, USA, with notes on the morphologically similar L. profundicola (Clitellata, Naididae, Tubificinae).

Fend SV, Liu Y, Steinmann D, Giere O, Barton HA, Luiszer F, Erséus C.

Zootaxa. 2016 Jan 18;4066(4):451-68. doi: 10.11646/zootaxa.4066.4.6.

PMID:
27395846
15.

Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK/PD Modeling Approach.

Chen X, Haddish-Berhane N, Moore P, Clark T, Yang Y, Li H, Xuan D, Barton HA, Betts AM, Barletta F.

Clin Pharmacol Ther. 2016 Sep;100(3):232-41. doi: 10.1002/cpt.393. Epub 2016 Jul 21.

PMID:
27170541
16.

Erratum to: Translational Modeling in Schizophrenia: Predicting Human Dopamine D₂ Receptor Occupancy.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2016 May;33(5):1305-6. doi: 10.1007/s11095-016-1888-2. Epub 2016 Mar 10. No abstract available.

17.

Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds.

Li R, Maurer TS, Sweeney K, Barton HA.

AAPS J. 2016 May;18(3):746-56. doi: 10.1208/s12248-016-9895-0. Epub 2016 Mar 7.

18.

Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2016 Apr;33(4):1003-17. doi: 10.1007/s11095-015-1846-4. Epub 2015 Dec 30. Erratum in: Pharm Res. 2016 May;33(5):1305-6.

PMID:
26718955
19.

A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions.

Li R, Barton HA, Maurer TS.

CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):338-49. doi: 10.1002/psp4.39. Epub 2015 Jun 1.

20.

Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays.

Shah F, Leung L, Barton HA, Will Y, Rodrigues AD, Greene N, Aleo MD.

Toxicol Sci. 2015 Oct;147(2):500-14. doi: 10.1093/toxsci/kfv152. Epub 2015 Jul 23.

PMID:
26206150
21.

Modeling the environmental growth of Pseudogymnoascus destructans and its impact on the white-nose syndrome epidemic.

Reynolds HT, Ingersoll T, Barton HA.

J Wildl Dis. 2015 Apr;51(2):318-31. doi: 10.7589/2014-06-157. Epub 2015 Jan 14.

PMID:
25588008
22.

Microbial diversity in a Venezuelan orthoquartzite cave is dominated by the Chloroflexi (Class Ktedonobacterales) and Thaumarchaeota Group I.1c.

Barton HA, Giarrizzo JG, Suarez P, Robertson CE, Broering MJ, Banks ED, Vaishampayan PA, Venkateswaran K.

Front Microbiol. 2014 Nov 26;5:615. doi: 10.3389/fmicb.2014.00615. eCollection 2014.

23.

Planning considerations related to the organic contamination of Martian samples and implications for the Mars 2020 Rover.

Summons RE, Sessions AL, Allwood AC, Barton HA, Beaty DW, Blakkolb B, Canham J, Clark BC, Dworkin JP, Lin Y, Mathies R, Milkovich SM, Steele A.

Astrobiology. 2014 Dec;14(12):969-1027. doi: 10.1089/ast.2014.1244. No abstract available.

PMID:
25495496
24.

Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations.

Li R, Barton HA, Maurer TS.

CPT Pharmacometrics Syst Pharmacol. 2014 Dec 10;3:e151. doi: 10.1038/psp.2014.50.

25.

Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.

Woodhead JL, Yang K, Siler SQ, Watkins PB, Brouwer KL, Barton HA, Howell BA.

Front Pharmacol. 2014 Nov 7;5:240. doi: 10.3389/fphar.2014.00240. eCollection 2014.

26.

Whole-Genome Sequences of Five Oligotrophic Bacteria Isolated from Deep within Lechuguilla Cave, New Mexico.

Gan HY, Gan HM, Tarasco AM, Busairi NI, Barton HA, Hudson AO, Savka MA.

Genome Announc. 2014 Nov 6;2(6). pii: e01133-14. doi: 10.1128/genomeA.01133-14.

27.

Physiologically based pharmacokinetic prediction of telmisartan in human.

Li R, Ghosh A, Maurer TS, Kimoto E, Barton HA.

Drug Metab Dispos. 2014 Oct;42(10):1646-55. doi: 10.1124/dmd.114.058461. Epub 2014 Aug 4.

PMID:
25092714
28.

Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.

Li R, Barton HA, Varma MV.

Clin Pharmacokinet. 2014 Aug;53(8):659-78. doi: 10.1007/s40262-014-0156-z. Review.

PMID:
25056496
29.

Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.

Johnson M, Kozielska M, Pilla Reddy V, Vermeulen A, Barton HA, Grimwood S, de Greef R, Groothuis GM, Danhof M, Proost JH.

Pharm Res. 2014 Oct;31(10):2605-17. doi: 10.1007/s11095-014-1358-7. Epub 2014 May 3.

PMID:
24792824
30.

A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling.

Li R, Barton HA, Yates PD, Ghosh A, Wolford AC, Riccardi KA, Maurer TS.

J Pharmacokinet Pharmacodyn. 2014 Jun;41(3):197-209. doi: 10.1007/s10928-014-9357-1. Epub 2014 Apr 10.

PMID:
24718648
31.

Comparison of the white-nose syndrome agent Pseudogymnoascus destructans to cave-dwelling relatives suggests reduced saprotrophic enzyme activity.

Reynolds HT, Barton HA.

PLoS One. 2014 Jan 22;9(1):e86437. doi: 10.1371/journal.pone.0086437. eCollection 2014.

32.

White-Nose Syndrome: Human Activity in the Emergence of an Extirpating Mycosis.

Reynolds HT, Barton HA.

Microbiol Spectr. 2013 Dec;1(2). doi: 10.1128/microbiolspec.OH-0008-2012.

PMID:
26184962
33.

The genome of Pseudomonas fluorescens strain R124 demonstrates phenotypic adaptation to the mineral environment.

Barton MD, Petronio M, Giarrizzo JG, Bowling BV, Barton HA.

J Bacteriol. 2013 Nov;195(21):4793-803. doi: 10.1128/JB.00825-13. Epub 2013 Aug 30.

34.

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.

Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM.

J Pharmacokinet Pharmacodyn. 2013 Oct;40(5):557-71. doi: 10.1007/s10928-013-9329-x. Epub 2013 Aug 10.

PMID:
23933716
35.

Genomer--a Swiss army knife for genome scaffolding.

Barton MD, Barton HA.

PLoS One. 2013 Jun 24;8(6):e66922. doi: 10.1371/journal.pone.0066922. Print 2013.

36.

Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment.

Meek ME, Barton HA, Bessems JG, Lipscomb JC, Krishnan K.

Regul Toxicol Pharmacol. 2013 Jun;66(1):116-29. doi: 10.1016/j.yrtph.2013.03.005. Epub 2013 Mar 25.

PMID:
23535119
37.

Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.

Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, Lin J, Varma MV.

Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):459-72. doi: 10.1517/17425255.2013.759210. Epub 2013 Jan 21. Review.

PMID:
23331046
38.

A multiscale, mechanism-driven, dynamic model for the effects of 5α-reductase inhibition on prostate maintenance.

Zager MG, Barton HA.

PLoS One. 2012;7(9):e44359. doi: 10.1371/journal.pone.0044359. Epub 2012 Sep 6.

39.

Cerebrospinal fluid β-Amyloid turnover in the mouse, dog, monkey and human evaluated by systematic quantitative analyses.

Lu Y, Barton HA, Leung L, Zhang L, Hajos-Korcsok E, Nolan CE, Liu J, Becker SL, Wood KM, Robshaw AE, Taylor CK, O'Neill BT, Brodney MA, Riddell D.

Neurodegener Dis. 2013;12(1):36-50. doi: 10.1159/000341217. Epub 2012 Aug 21.

PMID:
22922480
40.

Scaffolder - software for manual genome scaffolding.

Barton MD, Barton HA.

Source Code Biol Med. 2012 May 28;7(1):4. doi: 10.1186/1751-0473-7-4.

41.

Antibiotic resistance is prevalent in an isolated cave microbiome.

Bhullar K, Waglechner N, Pawlowski A, Koteva K, Banks ED, Johnston MD, Barton HA, Wright GD.

PLoS One. 2012;7(4):e34953. doi: 10.1371/journal.pone.0034953. Epub 2012 Apr 11.

42.

In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation.

Bi YA, Kimoto E, Sevidal S, Jones HM, Barton HA, Kempshall S, Whalen KM, Zhang H, Ji C, Fenner KS, El-Kattan AF, Lai Y.

Drug Metab Dispos. 2012 Jun;40(6):1085-92. doi: 10.1124/dmd.111.043489. Epub 2012 Mar 1. Review.

PMID:
22381335
43.

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, Fenner KS.

Drug Metab Dispos. 2012 May;40(5):1007-17. doi: 10.1124/dmd.111.042994. Epub 2012 Feb 16.

PMID:
22344703
44.

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.

Fenner KS, Jones HM, Ullah M, Kempshall S, Dickins M, Lai Y, Morgan P, Barton HA.

Xenobiotica. 2012 Jan;42(1):28-45. doi: 10.3109/00498254.2011.626464. Epub 2011 Nov 11. Review.

PMID:
22077101
45.

Microbial atrazine breakdown in a karst groundwater system and its effect on ecosystem energetics.

Iker BC, Kambesis P, Oehrle SA, Groves C, Barton HA.

J Environ Qual. 2010 Feb 19;39(2):509-18. doi: 10.2134/jeq2009.0048. Print 2010 Mar-Apr.

PMID:
20176824
46.

4.7 Biological modeling as a method for data evaluation and integration in toxicology.

Barton HA.

Hum Exp Toxicol. 2009 Feb;28(2-3):143-5. doi: 10.1177/0960327109105774. Review. No abstract available.

PMID:
19713382
47.

Pharmacokinetic modeling of perfluorooctanoic acid during gestation and lactation in the mouse.

Rodriguez CE, Setzer RW, Barton HA.

Reprod Toxicol. 2009 Jun;27(3-4):373-386. doi: 10.1016/j.reprotox.2009.02.009. Epub 2009 Mar 4.

PMID:
19429408
48.

Comparing models for perfluorooctanoic acid pharmacokinetics using Bayesian analysis.

Wambaugh JF, Barton HA, Setzer RW.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):683-712. doi: 10.1007/s10928-008-9108-2. Epub 2009 Jan 8.

PMID:
19130186
49.

Database for physiologically based pharmacokinetic (PBPK) modeling: physiological data for healthy and health-impaired elderly.

Thompson CM, Johns DO, Sonawane B, Barton HA, Hattis D, Tardif R, Krishnan K.

J Toxicol Environ Health B Crit Rev. 2009 Jan;12(1):1-24. doi: 10.1080/10937400802545060. Review.

PMID:
19117207
50.

Modeling single and repeated dose pharmacokinetics of PFOA in mice.

Lou I, Wambaugh JF, Lau C, Hanson RG, Lindstrom AB, Strynar MJ, Zehr RD, Setzer RW, Barton HA.

Toxicol Sci. 2009 Feb;107(2):331-41. doi: 10.1093/toxsci/kfn234. Epub 2008 Nov 12.

PMID:
19005225

Supplemental Content

Loading ...
Support Center